Keynote at ISIR World Congress... Introduces Korea's stem cell research strategy
"Plans to build an AI-powered cell bank"
Highlights potential to extend women's healthspan by delaying ovarian aging

Cha Kwang-ryul, head of the Global Comprehensive Research Institute at CHA Hospital and CHA Bio Group, outlined a strategy for securing cells to treat intractable diseases and a vision for extending healthspan by delaying ovarian aging.


CHA Hospital and CHA Bio Group announced on November 11 that Cha delivered a keynote address on “Longevity and Reproductive Aging Using K-Cell” at the 16th ISIR World Congress, held at BEXCO in Busan from November 5 to 8. Around 400 people attended the event.


Cha Kwangryul, head of the Global Comprehensive Research Institute at CHA Hospital and CHA Bio Group, delivers a keynote address at the 16th World Congress of the International Society for Immunology of Reproduction (ISIR World Congress), held at BEXCO in Busan on the 6th. CHA Bio Group

Cha Kwangryul, head of the Global Comprehensive Research Institute at CHA Hospital and CHA Bio Group, delivers a keynote address at the 16th World Congress of the International Society for Immunology of Reproduction (ISIR World Congress), held at BEXCO in Busan on the 6th. CHA Bio Group

View original image

Cha identified developing treatments for intractable diseases as K-Cell’s primary goal. The plan is to select cells suited to the treatment of specific diseases by comprehensively assessing donors’ ages and health, family medical histories spanning three generations, and whole-genome analyses, then secure cellular resources using techniques such as genetic modification and somatic cell nuclear transfer.


He also presented a long-term vision of extending healthspan and lifespan through research into ovarian aging. Based on research indicating that maintaining ovarian function can affect women’s healthspan and lifespan, he framed ovarian aging as an issue linked to women’s health throughout their lives, beyond pregnancy and childbirth. He also introduced an ongoing clinical study at Bundang CHA Hospital on premature ovarian insufficiency using umbilical cord-derived mesenchymal stem cells.


As infrastructure to support cell procurement and research and development, he introduced CGB (Cell Gene Bioplatform), a cell and gene therapy platform scheduled to open in early 2027. The plan is to establish cell banks containing various types of stem cells and immune cells, and use artificial intelligence (AI) to supply cells suited to specific diseases to researchers, hospitals, and biotechnology companies.



CHA Hospital and CHA Bio Group plan to prioritize developing treatments for intractable diseases using K-Cell, then expand this work into longevity and lifespan-extension research.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing